Would you use a platinum containing regimen such as docetaxel + carboplatin for an aggressive ER+ breast cancer in a patient with a deleterious mutation in ATM?

We do not have any data on ATM germline mutation carriers in regards to platinum use. Therefore, the decision to use platinum should be made independently from the ATM mutation.